New treatment option for hereditary angioedema - hope for patients!

New treatment option for hereditary angioedema - hope for patients!

The European Medicines Agency (EMA) has approved the subcutaneous administration of Takhzyro® (Lanadelumab), which is now available as a further treatment option for young people aged 12 and over and adults with hereditary angioedema (HAE). This was announced by Takeda (TSE: 4502/NYSE: TAK) and thus confirmed his commitment to the HAE community, which aims to improve the quality of life of the patients and to expand the existing treatment options. According to ots.at is The subcutaneous variant is a decisive development to reduce the HAE burden, which, according to estimates, concerns about 1 out of 50,000 people worldwide.

Innovative treatment options for Hae patients

The subcutaneous form of takhzyro enables easier and more convenient use for patients, which significantly increases treatment comfort. Takeda emphasizes that the new 2 ml finish option, which contains 300 mg of Lanadelumab, is the result of extensive clinical studies that demonstrate security and effectiveness. "The rapid approval of this additional option is a milestone for the treatment of HAE," said Irmgard Andresen, Global Medical Lead Hae near Takeda. "Now Hae patients from the age of 12 have an individualized treatment option that is available to them in critical times," she added.

In the USA, Takhzyro was also introduced as a ready -to -use injection injection, which enables more efficient administration of therapy, such as Takeda.com reported. The dose contained in this syringe can significantly simplify the treatment of HAE attacks for mutual care and self-employment. Takhzyro was examined in one of the largest studies on HAE prevention and has proven to be effective to reduce the frequency of seizures that can be extremely stressful for the patients and sometimes even life-threatening.